Rash and hyperglycaemia AEs had a lower incidence compared with the alpelisib trials; however, gastrointestinal AEs were reported more often for taselisib.12 These differences between the alpelisib and taselisib AE-profile could be attributed to the inhibitory effects on the different PI3K isoforms.11 The gene discussed is PIK3CA; the disease is Skin rash.